EWTX
HealthcareEdgewise Therapeutics, Inc. · Biotechnology · $4B
What is Edgewise Therapeutics, Inc.?
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for serious musculoskeletal diseases, including rare genetic muscle disorders.
Edgewise targets key muscle proteins to address genetically defined muscle disorders. Its lead candidate, EDG-5506, is an oral small molecule designed to treat dystrophinopathies such as Duchenne and Becker muscular dystrophy. The company generates no product revenue yet, funding operations through capital raises while advancing its pipeline through clinical trials.
Incorporated in 2017 and headquartered in Boulder, Colorado.
- EDG-5506 — oral small molecule for Duchenne and Becker muscular dystrophy
- Precision medicine pipeline targeting muscle protein modulators
- Genetically defined rare disease focus
Is EWTX a Good Stock to Buy?
UQS Score rates EWTX as Poor overall.
The Risk pillar stands out as the relative bright spot, reflecting a profile that is more measured than many early-stage peers in the rare disease space.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue clinical-stage company, while Valuation is rated Elevated.
See the full pillar breakdown and detailed financial metrics by signing up for a Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does EWTX pay dividends?
No — Edgewise Therapeutics, Inc. does not currently pay a dividend.
Edgewise Therapeutics does not pay a dividend. As a clinical-stage company with no commercial revenue, available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions.
When does EWTX report earnings?
Edgewise Therapeutics reports financial results on a quarterly cadence, typical for US-listed equities.
As a pre-revenue biopharmaceutical company, quarterly results center on operating expenses, cash runway, and clinical progress rather than sales or profitability. Pipeline milestones tend to be the primary market-moving events.
For the most recent quarter's results, visit Edgewise Therapeutics' investor relations page.
EWTX Price History
+12.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Edgewise Therapeutics, Inc.?
Based on Edgewise Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Edgewise Therapeutics do?
Edgewise Therapeutics develops oral small molecule therapies for rare musculoskeletal diseases. Its lead program targets dystrophinopathies, including Duchenne and Becker muscular dystrophy, by addressing the underlying muscle protein dysfunction rather than managing symptoms alone.
Does EWTX pay dividends?
No. Edgewise Therapeutics does not pay a dividend. The company is pre-revenue and reinvests all available capital into clinical development and pipeline expansion.
When does EWTX report earnings?
EWTX reports on a standard quarterly schedule. Because the company is clinical-stage, pipeline updates often matter more than financial results. Check the Edgewise Therapeutics investor relations page for the current reporting calendar.
Is EWTX a good stock to buy?
The UQS Score rates EWTX as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. The Risk pillar is the relative strength. Pro members can view the complete pillar breakdown to form their own assessment.
Is EWTX overvalued?
The UQS Valuation pillar for EWTX is rated Elevated, suggesting the market is pricing in significant future success relative to the company's current clinical and financial stage. This is common for high-potential rare disease biotechs but carries meaningful uncertainty.
What is EWTX's market cap bracket?
Edgewise Therapeutics falls in the mid-cap bracket, notable for a clinical-stage biopharmaceutical company that has yet to generate product revenue.
Who founded Edgewise Therapeutics?
Edgewise Therapeutics was incorporated in 2017. Founding and leadership details are publicly available on the company's website and SEC filings.
Is EWTX a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates EWTX as Poor, driven by Weak pillar scores across Quality, Moat, and Growth. Long-term quality typically improves as a company advances toward commercialization and builds durable competitive advantages.
Unlock Full EWTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare EWTX against sector peers on a like-for-like basis
- ✓Get the complete analyst-grade quality view in one place
Pro Analysis
EWTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 14.0 | 0.0 | 11.0 | 1.1 | 73.8 | 0.0 | +0.2 |
| May 9, 2026 | 13.8 | 0.0 | 11.0 | 0.0 | 73.8 | 0.0 | -0.2 |
| May 8, 2026 | 14.0 | 0.0 | 11.0 | 1.1 | 73.8 | 0.0 | +0.2 |
| Apr 22, 2026 | 13.8 | 0.0 | 11.0 | 1.1 | 72.3 | 0.0 | -0.1 |
| Apr 2, 2026 | 13.9 | 0.0 | 11.0 | 1.3 | 72.3 | 0.0 | — |
EWTX — Pillar Breakdown
Quality
— 0.0/100 (25%)Edgewise Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 1.1/100 (20%)Edgewise Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.8/100 (15%)Edgewise Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Edgewise Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Edgewise Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for EWTX.
Score Composition
Financial Data
More Stock Analysis
How is the EWTX UQS Score Calculated?
The UQS (Unified Quality Score) for Edgewise Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Edgewise Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Edgewise Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.